Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of DiagnosticsGlobeNewsWire • 03/25/24
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024GlobeNewsWire • 03/22/24
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to ShareholdersGlobeNewsWire • 03/18/24
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023GlobeNewsWire • 03/18/24
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User BaseGlobeNewsWire • 03/11/24
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure PatientsGlobeNewsWire • 03/08/24
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics ConferenceGlobeNewsWire • 02/26/24
Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer AcquisitionsGlobeNewsWire • 02/12/24
Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume AnalyzerGlobeNewsWire • 01/02/24
New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure PatientsGlobeNewsWire • 11/13/23
Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific MeetingGlobeNewsWire • 10/13/23
New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific MeetingGlobeNewsWire • 10/11/23
Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services ProgramGlobeNewsWire • 10/04/23
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023GlobeNewsWire • 09/27/23
Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis PatientsGlobeNewsWire • 09/11/23
Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/07/23
Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023GlobeNewsWire • 08/28/23
JACC-HF Study Compares Daxor's BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure PatientsGlobeNewsWire • 07/12/23
Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume AnalyzerGlobeNewsWire • 07/05/23
Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary OfferingGlobeNewsWire • 06/22/23
Daxor Corporation to Participate in the Maxim Group Virtual Healthcare ConferenceGlobeNewsWire • 06/12/23
Daxor Corporation Announces Closing of $4.0 Million Underwritten Public OfferingGlobeNewsWire • 05/25/23